- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04604483
Percutaneous Tibial Nerve Stimulation (PTNS) for the Treatment of Chronic Anal Fissure
February 29, 2024 updated by: Region Skane
Percutaneous Tibial Nerve Stimulation for Chronic Anal Fissure - a Prospective Study
Chronic anal fissure rarely heals spontaneously.
About 50% heal on administration om topical muscle relaxants (e.g.
diltiazem) and/or injection of Botulinum toxin, but for the remainder of patients surgery (with lateral internal sphincterotomy or fissurectomy) with subsequent risks of anal incontinence has been the golden standard.
Treatment with PTNS (percutaneous tibial nerve stimulation) has been showed to produce healing of chronic anal fissures not responding to topical treatment, thus avoiding the risk for debilitating anal incontinence.
Study Overview
Detailed Description
This study will prospectively include 52 patients with chronic anal fissure that have received topical treatment and stool softeners and have all been evaluated by experienced proctological surgeons.
The treatment will be given for 10 consecutive work days and then evaluated at 3 and 12 months.
If the patients symptoms are unimproved at 3 months alternative treatments will be offered.
Study Type
Interventional
Enrollment (Estimated)
52
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Martin Lindsten, MD
- Phone Number: +4640331000
- Email: martin.lindsten@skane.se
Study Contact Backup
- Name: Sara Strandberg
- Phone Number: +4640331000
- Email: sara.strandberg@skane.se
Study Locations
-
-
-
Malmo, Sweden
- Skåne University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Verified anal fissure (Clinical assessement by experienced proctological surgeon)
- Full conservative treatment has been given
Exclusion Criteria:
- Inflammatory bowel disease
- Fistula and/or anal abscess
- Patients with compromised immunity
- Pregnancy
- Treatment with anti-coagulants (not aspirin)
- Previous irradiation towards pelvic floor
- Pacemaker or implanted defibrillator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PTNS
Treatment with PTNS for chronic anal fissure, treatment to be given for 30 minutes during 10 consecutive work Days.
|
Patients meeting the criteria are treated with PTNS and are evaluated at 3 months and 1 year after end of treatment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Healing rate
Time Frame: 3 months after treatment
|
Healing of anal fissure from assessement of clinical and/or data from patient form
|
3 months after treatment
|
Healing rate
Time Frame: 12 months after treatment
|
Healing of anal fissure from assessement of clinical and/or data from patient form
|
12 months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bowel movements
Time Frame: 3 months after treatment
|
Changes in frequency of bowel emptying and consistency of bowel contents Before and after treatment
|
3 months after treatment
|
Bowel movements
Time Frame: 12 months after treatment
|
Changes in frequency of bowel emptying and consistency of bowel contents Before and after treatment
|
12 months after treatment
|
Adverse effects
Time Frame: 3 months after treatment
|
Reports of adverse effects (subjective/objective)
|
3 months after treatment
|
Adverse effects
Time Frame: 12 months after treatment
|
Reports of adverse effects (subjective/objective)
|
12 months after treatment
|
Smoking
Time Frame: 3 months after treatment
|
Differences in healing rates between smokers and non-smokers
|
3 months after treatment
|
Smoking
Time Frame: 12 months after treatment
|
Differences in healing rates between smokers and non-smokers
|
12 months after treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Louis B Johnson, PhD, Lund University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 1, 2024
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2026
Study Registration Dates
First Submitted
October 14, 2020
First Submitted That Met QC Criteria
October 21, 2020
First Posted (Actual)
October 27, 2020
Study Record Updates
Last Update Posted (Actual)
March 1, 2024
Last Update Submitted That Met QC Criteria
February 29, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PTNS for anal fissure
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
No intention to make individual participant data available to other researchers
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fissure in Ano
-
IpsenCompletedAnal FissureCzechia, Poland, Romania, Tunisia
-
Onze Lieve Vrouwe GasthuisCompleted
-
Dieter HahnloserCompleted
-
Biolab Sanus FarmaceuticaWithdrawn
-
Mansoura UniversityUnknown
-
Bispebjerg HospitalSacomedTerminated
-
Region SkaneCompleted
-
S.L.A. Pharma AGCompletedChronic Anal FissureUnited Kingdom, Spain, Bulgaria, Germany, Lithuania, Romania
-
Zagazig UniversityCompletedChronic Anal FissureEgypt
-
University of NinevehCompleted
Clinical Trials on PTNS
-
Shengjing HospitalCompletedConstipation | Pelvic Floor Disorders | Childhood ALLChina
-
Gnankang Sarah NapoeRecruitingUrinary Incontinence, Urge | Overactive Bladder SyndromeUnited States
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUnknownLow Anterior Resection Syndrome | Rectal CancerItaly
-
University of California, San DiegoCompletedOveractive Bladder SyndromeUnited States
-
Lundquist Institute for Biomedical Innovation at...UnknownOveractive BladderUnited States
-
Cantonal Hospital of St. GallenCompletedFecal IncontinenceSwitzerland
-
London North West Healthcare NHS TrustCompletedPelvic Floor Disorders | Faecal Incontinence
-
University of Kansas Medical CenterUnknown
-
William Beaumont HospitalsRecruitingMultiple Sclerosis | Overactive BladderUnited States
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknown